Dr. M. Tariq Khan

Assistant Professor

Dr. Muhammad Tariq Khan, a distinguished professional with a Ph.D. in Pharmacy (Pharmaceutical Chemistry) obtained through the HEC-Indigenous Scholarship Program at Riphah International University in 2021. His multifaceted career encompasses roles as a National Sales Manager, Product Manager, Lecturer, and Assistant Professor within the domains of pharmaceutical marketing and academia. Dr. Khan’s extensive expertise is emphasized by his significant contributions to medicinal chemistry, organic synthesis, molecular modeling, and docking, as well as molecular pharmacology. His research primarily revolves around the organic synthesis of lead molecules and organic moieties. His commitment to advancing knowledge is evident through numerous post-graduate research projects that he has successfully supervised in collaboration with esteemed colleagues. Dr. Muhammad Tariq Khan’s research has not only enriched the academic community but has also opened new avenues in the realm of pharmaceuticals, contributing to advancements with far-reaching implications. His dedication to academia and research exemplifies a commitment to excellence, making him an asset to the field.

PhD Pharmacy Riphah International University, Islamabad 2021
MPhil Pharmaceutical Chemistry Bahauddin Zakariya University, Multan 2014
Pharm.D Pharmaceutical Sciences University of Sargodha, Sargodha 2011
Assistant Professor Capital University of Science and Technology (CUST), Islamabad Since – 2021
Assistant Professor Margalla College of Pharmacy, Rawalpindi 2018 – 2018
Product Manager UniMark Pharmaceuticals Ltd. 2013 – 2014
Product Specialist 3A Pharmaceuticals Ltd. 2012 – 2012
PPC Member Punjab Pharmacy Council, Lahore
PPA Member Pakistan Pharmacist Association
1. Organic Synthesis
2. Drug Designing and Development
3. Pharmaceutical Chemistry
4. Virtual Drug Designing and In-Silico Screening
A. Bukhari, H. Nadeem, S. Sarwar, I. Abbasi, M. T. Khan, I. Hamid, U. Bukhari. “Exploring Therapeutic Potential of 1,3,4-Oxadiazole Nucleus as Anticancer Agents: A Mini-Review.” Medicinal Chemistry, 2022.
A.M. Zubair, M.N.H. Malik, W. Younis, M.A.H. Malik, S. Jahan, I. Ahmed, A. Yuchi, M.N. Mushtaq, R. Tahir, M.B. Sarwar, and M. Roman. A. A. Khan, M. N Tahir, M. T. Khan, H. A. A, Kharl, G. Kamran, A.A Albegali1, A. Imran. “Novel acetamide derivatives of 2-aminobenzimidazole prevent inflammatory arthritis in rats via suppression of pro-inflammatory mediators.” Inflammopharmacology, vol. 16, pp.1-15, 2022.
A.Batool, G.A. Miana, M. Alam, M. T Khan, M. Muddassir, W. Zaman, Saifullah, A. Aman, A. Khusroo, M. V. Arasu, N.A. Al-Dhabi, K.C. Choi, and M. U. K. Shahibzada. “Bioassay-guided fractionation and isolation of Arctigenin from Saussurea heteromalla for in vitro and in silico cytotoxic activity against HeLa cells.” Physiological and Molecular Plant Pathology, 101749, 2021.
N.S. Malik, M. Ahmad, M.S. Alqahtani, A. Mahmood, K. Barkat, M.T. Khan, U.R. Tulain, and A. Rashid, “β-cyclodextrin chitosan-based hydrogels with tunable pH-responsive properties for controlled release of acyclovir: design, characterization, safety, and pharmacokinetic evaluation”, Drug Delivery, vol. 28, no. 1, pp. 1093-1108, 2021
M. T. Khan, H. Nadeem, A. S. Sheikh, N. S. Malik, M. Rizwan, M. Imran, I. Javed. A. Khan, and M. Abbas, “Amino acid derivatives of 2-Mercaptobenzimidazoles suppress cytokines at the site of inflammation and block gastric H/K ATPase”, Pakistan Journal of Pharmaceutical Sciences, vol. 34, no. 3, pp. 1157-1163, 2021
H. R. Afzal., N. U. H. Khan., K. Sultana., A. Mubashir., A. Lareb., A. Khan., M. T. Khan., and M. Imran, “Schiff bases of pioglitazone provide better antidiabetic and potent antioxidant effect in a streptozotocin–nicotinamide-induced diabetic rodent model”, ACS Omega, vol. 06, no. 06, pp. 4470-4479, 2021
M. T. Khan, H. Nadeem, A. U. Khan, M. Abbas, M. Arif, N.S. Shamshad, Z. Malik, and I. Javed, “Amino acid conjugates of 2-mercaptobenzimidazole provide better anti-inflammatory pharmacology and improved toxicity profile”, Drug Development Research, vol. 81, no. 08,pp. 1057-1072, 2020
A. M. Alvi, L. T. A. Kury, M. U. Ijaz, F. A. Shah, M. T. Khan, A. S. Sheikh, H. Nadeem, A. Khan, A. Zeb, and S. Li, “Post-treatment of synthetic polyphenolic 1,3,4 oxadiazole compound A3, attenuated ischemic stroke-induced neuroinflammation and neurodegeneration”, Biomolecules, vol. 10, no. 1, pp. 816, 2020
S. Iqbal, F. A. Shah, K. Naeem, H. Nadeem, S. Sarwar, Z. Ashraf, M. Imran, T. Khan, T. Anwar, and S. Li,“Succinamide derivatives ameliorate neuroinflammation and oxidative stress in scopolamine-induced neurodegeneration”, Biomolecules, vol. 10, no. 3, pp. 443, 2020
M. T. Khan, M. T. Razi, S. U. Jan, M. Mukhtiar, R. Gul, I. Ullah, A. Hussain, A. M. Hashmi, M. T. Ahmad, N. A. Shahwani, and I. Rabbani, “Synthesis characterization and antihypertensive activity of 2-Phenyl substituted benzimidazoles”, Pakistan Journal of Pharmaceutical Sciences, vol. 31, no.3, pp. 1067-1074, 2018
M. Hanif, H. U. Khan, S. Afzal, M. T. Khan, K. Afzal, and N. Iqbal, “Sustained release ivabradine lipospheres from camauba wax/stearic acid blend: formulation, evaluation, and optimization by central composite design”, Latin American Journal of Pharmacy, vol. 36, no. 1, pp. 25-36, 2017
H. Khan, A. Mahmood, S. Maheen, R. M. Sarfaraz, A. Youchi, A. Shameem, M. Akhtar, H. Ahsen, M. T. Khan, M. Khalil, and T. M. Rana, “Formulation and in vitro evaluation of novel antidiabetic orodispersible tablets using kyron-t134 and crosscaramellose sodium as superdisintegrants”, Latin American Journal of Pharmacy, vol. 33, no. 4, pp. 631-639, 2014
M. T. Razi, I. Javed, M. Z. Choudhary, M. T. Khan, and N. Mukhtar, “Effect of ketoprofen on lactic dehydrogenase from human platelets”, Advances in Clinical and Experimental Medicine, vol. 23, no. 3, pp. 377-380, 2013

Other Members